A Phase 3 Study to Assess the Immune Response and Safety of rMenB+OMV NZ in Primed Healthy Participants (10 to 20 Years Old)
Key facts
- Who runs it
- GlaxoSmithKline
- Where
- Finland, Italy, Spain, and United Kingdom17 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 312 people enrolled
- Started
- 7 Jul 2025
- Ended
- 15 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- rMenB+OMV NZ vaccine
- Record updated
- 6 November 2026
Who can take part
- Age
- 10 years to 20 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- Participants were eligible to be included in the study only if all of the following criteria applied:
- For primed group only:
- Participated who were primed with rMenB + OMV NZ in only either 3+1 or 2+1 schedule during the first 2 years of life as confirmed by electronic or paper vaccination record; OR; For naïve group only:
- Electronic or paper vaccination record confirmed participant who has never received any group B meningococcal vaccine and is recruited in the same country as primed participants; For all participants:
- Participants and/or participants' parent(s)/ legally acceptable representative(s) (LAR[s]), who, in the opinion of the investigator, can and will comply with the requirements of the protocol
- Written or witnessed/thumb printed informed consent obtained from the participant / parent(s)/LAR(s) of the participant prior to performance of any study-specific procedure
- Written informed assent obtained from the participant (if applicable) along with informed consent from the participant's parent(s)/LAR(s) prior to performing any study specific procedure; Note: For age 10-16 years, parents or LAR to give consent along with participants, based on country regulations for participants and for >16/18 to 20 years, participants give consent independent of parents/LARs, or as per local country regulations
- A male or female between, and including, 10 and 20 years of age at the time of the first study intervention administration
- Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, hysterectomy, bilateral ovariectomy
- Female participants of childbearing potential may be enrolled in the study, if the participant:; has practiced adequate contraception for 1 month prior to study intervention administration, and; has a negative pregnancy test on the day of study intervention administration, and; has agreed to continue adequate contraception during the entire study treatment period
Who cannot take part
- Current or previous, confirmed or suspected disease caused by N. meningitidis
- Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study; Prior/Concomitant therapy
- Use of any investigational or non-registered product (drug, vaccine or medical device) other than the study intervention during the period beginning 30 days before the first dose of study intervention (Day -29 to Day 1), or their planned use during the study period
- Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the end of the study; Within 90 days prior to study intervention administration: for corticosteroids, this will mean prednisone equivalent >=20 milligram (mg)/day for adult participants or >=0.5 mg/kg/day with maximum of 20 mg/day for pediatric participants. Inhaled and topical steroids are allowed; Within 90 days prior to study intervention administration: long-acting immune-modifying drugs including among others immunotherapy (e.g., TNF-inhibitors), monoclonal antibodies, antitumoral medication
- Administration of immunoglobulins and/or any blood products or plasma derivatives within 180 days prior to study intervention administration and/or planned use at any time up to the end of the study; For primed group only:
- Participants who received additional dose(s) of group B meningococcal vaccine other than 2+1 or 3+1 schedule prior to study intervention administration; Prior/Concurrent clinical study experience
- Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/vaccine/invasive medical device); Other exclusion criteria
- Medical conditions
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention
- Medical conditions representing a contraindication to intramuscular vaccination and blood draws
- Known exposure to an individual with laboratory confirmed N. meningitidis infection, within 60 days prior to enrollment
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required)
- Participants were excluded from the study if any of the following criteria applied:
- Pregnant or lactating female participant
- Any study personnel or their immediate dependents, family, or household member
- Child in care
This trial has no sites in United States.
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main purpose of this study was to evaluate the immune response and safety of a booster dose of the meningococcal group B vaccine, rMenB+OMV NZ (also known as Bexsero), in adolescents and young adults aged 10 to 20 years. This study focused on individuals who were first vaccinated with rMenB+OMV NZ as infants. The primary hypothesis was that a booster dose of the vaccine would elicit a stronger immune response in these primed individuals compared to those who had never received any group B meningococcal vaccine, referred to as 'naïve' participants.
The 2 groups in the trial
- Primed groupTreatment being tested
Participants who were primed with rMenB+OMV NZ vaccine in a 3 (2+1) doses or 4 (3+1) doses vaccination schedule during the first 2 years of life, received 1 dose of rMenB+OMV NZ vaccine at Day 1.
Treatment: rMenB+OMV NZ vaccine
- Naïve groupExisting treatment, for comparison
Participants who never received any group B meningococcal vaccine previously, received 2 doses of rMenB+OMV NZ vaccine, one at Day 1 and one at Day 31.
Treatment: rMenB+OMV NZ vaccine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3b, Open-Label, Multi-Center Study to Assess the Immune Response and Safety of the Meningococcal Group B Vaccine rMenB+OMV NZ When Administered to Healthy Participants Aged 10 to 20 Years Old, Who Were Primed During the First 2 Years of Life
- Record updated
- 6 November 2026